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Multidrug resistance: Versatile drug sensors of bacterial cells
Kim Lewis
One way that bacteria resist antimicrobial agents
involves ‘drug sensors’, proteins that bind a range of
structurally unrelated antimicrobial drugs and induce
expression of multidrug resistance pumps. The basis for
drug recognition is now becoming clear from the
recently determined crystal structure of a drug sensor.
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The emergence of multidrug resistance is undoubtedly
the focal point in our current relationship with pro-
karyotes. Antibiotic resistance is nothing new and has
evolved in bacteria over the millennia of fighting a chemi-
cal war first with each other, and then with fungi and
plants. What is new is our realization of the ease with
which a particular pathogen is able to recruit drug resis-
tance from outside sources. Important new insights into
one key drug resistance mechanism have come from the
recently determined crystal structure of a protein capable
of sensing a wide range of antimicrobial drugs and induc-
ing expression of protein pumps that act to rid the cell of
the drug molecules.
The instant acquisition by a bacterial cell of resistance to
five or six different antibiotics initially seemed like
breaking of all the rules. It is implausible that five
mutations could arise simultaneously — at a rate of 10–7
per mutation, the probability of this happening would be
(10–7)5 or 10–35. The riddle was solved when it was found
that cells can pick up a plasmid that confers resistance to
five antibiotics. This finding seemed to set the stage for
an intelligent solution to the problem of drug resistance. It
is reasonable to expect that resistance mechanisms have
evolved for each and every natural antimicrobial com-
pound. This means that, sooner or later, the resistance
mechanism will move from its unknown host onto a
plasmid and into a human pathogen.
One solution to this problem would be to make synthetic
antibiotics that would not be subject to pre-existing
resistance mechanisms. This is not a foolproof strategy, as
the bacterial protein targeted by the synthetic antibiotic
would still be subject to mutation — but such a mutation
might decrease the fitness of the organism. More
importantly, one might expect that a synthetic drug would
not be subject to the very potent specific resistance
mechanisms bacteria have evolved, such as the enzymes
that destroy natural antibiotics — for example, β-lacta-
mase cleaves penicillins and acetyl transferase modifies
aminoglycosides — or the transmembrane pumps that
extrude them from the cell — such as the tetracycline
extrusion pump.
This logic proved simplistic when multidrug resistance
pumps were discovered in bacteria [1–5]. These
membrane proteins extrude a variety of chemically unre-
lated antimicrobial agents from the cell. As they do not
rely on structure recognition in selecting their substrates,
it is not surprising that multidrug resistance pumps
extrude artificial antimicrobial agents perfectly well. For
example, clinical resistance to synthetic quinolones in
Pseudomonas aeruginosa is largely due to the expression of
the MexAB–OprM pump [6]. 
With multidrug resistance pumps, bacteria might have hit
upon a design for a ‘perfect defense’. If a multidrug
resistance pump can extrude any toxin from the cell, then
bacteria already have in their possession a powerful defense
mechanism against the future wonder drugs that are
moving through the pipe-lines of combinatorial chemistry
programs. The multidrug resistance pumps are especially
effective in gram-negative bacteria, where they extrude
toxins across the outer membrane. The outer membrane of
a gram-negative bacterial cell is a good barrier for amphi-
pathic antimicrobial agents, and the synergy between a
restrictive barrier to permeation and efflux across this
barrier is what turns the gram-negative multidrug resistance
pumps into a potent defense mechanism.
How can a single protein extrude chemically unrelated
drugs and also distinguish them from all cellular
molecules? This seemingly impossible task could be
accomplished if the protein recognizes primarily polarity,
rather than structure. Antibiotics with intracellular
targets have to be amphipathic molecules in order to
cross the membrane. Cellular compounds, on the other
hand, have to be hydrophilic in order to stay in the cell.
A protein with a large amphipathic pocket could selec-
tively bind the more hydrophobic toxins and ignore the
cellular compounds.
One can marvel at the inventiveness of nature in pro-
ducing multidrug resistance pumps. But one can, and in
fact should, also consider the likelihood of nature being
less than perfect in this respect. This thinking is behind
the notion of a ‘sloppy translocase’ [7], which holds that
each multidrug resistance pump evolved to protect the
cell from a particular antibiotic, but that the proteins are
not very specific, leading to the ‘multidrug resistance’
phenomenon. It is not obvious that this is a falsifiable
hypothesis — how do you test for unknown natural com-
pounds? — but this does not make it any less probable. 
The first evidence against the sloppy translocase model
came from the finding by Ahmed et al. [8] of a trans-
criptional activator that controls the expression of the Bmr
multidrug pump in a gram-positive Bacillus subtilis. Antimi-
crobial substrates of the Bmr pump, such as rhodamine or
tetraphenyl phosphonium, induce the expression of the
gene encoding the pump protein (Figure 1). This induc-
tion is mediated by the BmrR regulator, which was shown
to bind many of the various substrates of the pump and
activate transcription of its gene. It appeared that the cell
uses a special multidrug sensor to detect the presence of
potential toxins. This detection leads to increased produc-
tion of the pump that extrudes toxins from the cell. The
existence of a multidrug sensor suggests that Bmr is a spe-
cialized multidrug pump after all.
Another multidrug sensor was discovered in the course of
our studies of the adaptation of Escherichia coli to
uncouplers of oxidative phosphorylation. These synthetic
compounds are protonophores that collapse the cell’s
proton motive force. Natural protonophores are not known,
yet cells clearly demonstrated an ability to adapt to a
variety of these substances. A search for the mechanism of
this adaptation led to the cloning of the gene encoding the
EmrAB multidrug pump [3]. Subsequent studies showed
that the pump is induced in the presence of protonophores
and the weak acid salicylate. The induction is controlled
by the EmrR multidrug sensor, which is a repressor of the
emrAB operon [9]. The EmrR protein belongs to the MarR
family of repressors and is a helix–turn–helix type DNA-
binding protein. It exists in the form of a dimer, and the
pure protein binds substances such as dinitrophenol,
CCCP and FCCP with micromolar affinity.
The third known multidrug sensor was discovered by
Skurray and colleagues [10], who were studying the
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Figure 1
Drug sensors and the pumps they control.
(a) The BmrR sensor is encoded by the bmrR
gene, located immediately downstream of
bmr, which encodes the pump. Interaction
with a cationic antimicrobial agent such as
TPP induces binding of BmrR to the promoter
region and activation of bmr transcription. The
Bmr pump is a drug–proton antiporter that
extrudes drugs from the cell. (b) The QacR
sensor is transcribed from a gene positioned
divergently in respect to qacA, which encodes
the pump. Binding of QacR to drugs releases
it from the operator sequence and induces
transcription of qacA (c) The EmrR sensor
binds mostly weakly acidic compounds such
as the protonophore CCCP. EmrR represses
transcription of the emrRAB operon, but this
is relieved when EmrR binds a cognate drug
and is released from the operator.
EmrAB/TolC is a multicomponent pump that
spans both membranes of the gram-negative
E. coli cell.
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QacA multidrug resistance pump in the pathogen Staphy-
lococcus aureus. QacA belongs to the same ‘major facilita-
tor’ family of drug antiporters as Bmr, and also extrudes
hydrophobic cations from the cell. QacA helps S. aureus
resist cationic antiseptics such as benzalkonium chloride
and chlorhexidine. QacA substrates were found to
induce the pump, and the regulator was identified as a
transcriptional repressor of the TetR family. QacR binds
many of the cationic substrates of QacA and is released
from the DNA. A related TetR repressor binds tetracy-
cline and controls a specific tetracycline efflux pump.
Interestingly, although QacR has the same function as
the drug sensor BmrR, binds a similar spectrum of
ligands and regulates a related pump, it shows no simi-
larity to BmrR.
The drug sensors are providing us with useful insights into
the functions of multidrug resistance pumps and will
undoubtedly be very useful in searching for natural mul-
tidrug resistance pump substrates. There is another area
where the drug sensors can make a significant impact on
our understanding of the phenomenon of multidrug resis-
tance. Much effort has been expended on understanding
the mechanism of multidrug resistance pumps, and much
useful information has been obtained. The inevitable
limitation of these studies has been the lack of good struc-
tural methods to access the tertiary structure of the
complex membrane proteins. The drug sensors share an
important feature with the larger transporters they regu-
late, which is the remarkable ability to discriminate
between drugs and self molecules. Understanding how
the small regulators do this will be very useful in helping
to decipher the workings of the pumps.
Structure of the BmrR drug-binding site
The most interesting part of a multidrug resistance pump is
of course its drug-binding site, and this is undoubtedly also
true of the drug sensors. A distinct domain assignment has
been made for proteins like BmrR, which belong to the
MerR family of transcriptional activators. These proteins all
have a similar amino-terminal DNA-binding domain, but
show little homology in their carboxy-terminal, apparently
ligand-binding domain. This helped to further ‘simplify’
BmrR for structural studies. An 18 kDa carboxy-terminal
fragment retained the ability of the native 32 kDa protein
to form dimers and bind ligands. This ligand-binding frag-
ment was successfully crystallized, and its three-dimen-
sional structure has recently been reported by Zheleznova
et al. [11]. At last, one can gaze into a binding site that
accommodates structurally unrelated drugs. 
The first impression from looking at the crystal structure
of the BmrR fragment is that there is no binding site
within the compact structure of the folded protein. The
binding site revealed itself, at 2.8 Å resolution, when the
BmrR fragment was crystallized with the ligand
tetraphenylphosphonium (TPP) (Figure 2). Apparently,
one of the protein’s α helices gates an opening into a
hydrophobic pocket. The ligand displaces the α helix and
enters the pocket. Interestingly, this process involves the
melting of the α helix. This could potentially cause a large
conformational change in the protein, resulting in untwist-
ing of the bound DNA and properly positioning the
promoter sequences recognized by RNA polymerase.
Once inside the binding site, TPP interacts with a series
of hydrophobic residues that make up its surface. The
phenyl rings of TPP form van der Waals contacts with the
side chains of isoleucine, valine and alanine, and at least
one of the rings stacks against a tyrosine residue. The
bottom of the pocket contains an unusually positioned
glutamate residue, buried in a hydrophobic environment
and forming hydrogen bonds with tyrosine residues. One
of the rings of TPP — which carries part of the delocalized
positive charge — contacts this glutamate. 
TPP binds BmrR with a modest dissociation constant (Kd)
of 100 µM; rhodamine binds much more tightly
(Kd = 1 µM), but efforts to crystallize the BmrR fragment
with this much better ligand were unsuccessful. One
might expect that a protein should crystallize better with a
ligand that forms a tighter bond. The questions of why
this is not the case will have to wait for the art of growing
crystals to transform itself into an exact science. For now,
one can look at an in silico model the authors constructed
by replacing TPP with rhodamine. Zhelznova et al. [11]
found that the very different molecule rhodamine fits into
the same pocket as TPP. The charged nitrogen of rho-
damine forms a closer contact with glutamate, which
would explain the tighter binding. 
The structure of the binding site of BmrR does look dis-
tinctly different from a typical binding pocket of a recep-
tor or an enzyme. It can be roughly approximated by a
cone with a hydrophobic inner surface and a negative
charge at the tip. Two main components generally ensure
tight and specific ligand binding: polar interactions with
tightly fitting groups of the protein and the ligand, and a
general stereospecific match with the binding pocket.
Both types of interaction are conspicuously absent in the
BmrR–ligand complex. It seems that the hydrophobic
cone will accommodate a large number of hydrophobic
molecules, the affinity being determined by the ionic
interaction with the glutamate and the relative surface
contact and stacking between the hydrophobic groups of
the ligand and the binding site. To put it plainly, BmrR
seems to have been designed to discriminate molecules
largely on the basis of polarity.
Why hydrophobic cations?
Functional studies and structural analysis both suggest
that BmrR evolved to detect chemically unrelated
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hydrophobic cations. This seems to make sense, given
that hydrophobic cations are substrates of the Bmr pump
that BmrR regulates. Interestingly, hydrophobic cations
are the only substrates for small multidrug resistance
pumps of the SMR family, are preferred substrates for
most multidrug resistance pumps of the MF and ABC
families, and are among the substrates of the versatile
RND family of multidrug resistance pumps. Hydrophobic
cations are also preferred substrates for the P-glycoprotein
multidrug resistance pump, a member of the ABC family
that is responsible for multidrug resistance of human
tumors [12]. This makes understanding the binding and
extrusion of cationic substances highly significant.
Did multidrug resistance pumps and their sensors
originally evolve to combat cationic antimicrobial agents?
We know of many very effective cationic antimicrobial
agents, potent antiseptics such as benzalkonium chloride
and ethidium bromide. The problem is, all these com-
pounds are synthetic and not a single known natural
antibiotic is a hydrophobic cation. This is especially sur-
prising considering that a positive charge on a molecule
will increase its accumulation in the bacterial cell. The
membrane of a bacterial cell is charged by proton pumps
and maintains a ∆Ψ of about 120–180 mV. According to
the Nernst equation, there is a 10-fold accumulation of a
cation for every 60 mV of the membrane potential. This
means that an antibiotic carrying a positive charge will
accumulate in the cell 100–1000-fold, and will be that
much more potent than a similar neutral molecule. (Many
natural compounds are weak bases that form cations upon
protonation but these only penetrate in the neutral form
and are extruded from the cell by the pH gradient, which
does not make them good antibiotics.)
The fact that amphipathic cations are conspicuously
absent from known natural antibiotics is especially puz-
zling given that they are the preferred substrates for most
multidrug resistance pumps. We have argued that it is pre-
cisely the existence of multidrug resistance pumps that is
responsible for this apparent paradox [13]. If multidrug
resistance pumps evolved in response to natural anti-
microbial amphipathic cations, then these substances
would be difficult to discover in standard screens that
employ cells carrying multidrug resistance pumps. In the
process of drug discovery, the concentration of antimicro-
bial agents is prone to be low, and multidrug resistance
pump substrates will be overlooked.
For this reason, we suggested that cells with mutations
abolishing the function of their multidrug resistance
pumps could be used to increase the sensitivity of screens
for new antimicrobial agents. While using such mutants is
a reasonable, if somewhat unpredictable, way to discover
possible cationic antimicrobial agents, another approach is
to search for possible substrates of multidrug resistance
pumps among known compounds. Many natural sub-
stances have been described as a result of systematic
chemical analysis of organisms, rather than in particular
bioassay-driven purifications. One would then look for
substances that are amphipathic cations of natural origin
that have little or no antimicrobial activity.
Using these criteria, we identified a group of plant
alkaloids whose members have little or no antimicrobial
activity. These are the berberine alkaloids, which are
widely spread among the plant world and are found among
many Ranunculales species, for example. These substances
bear a resemblance to artificial substrates of multidrug
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Figure 2
(a) Structures of the BmrR fragment in the
absence (top) and presence (bottom) of
bound ligand (TPP). Most of the protein chain
is represented as a cyan ribbon. Upon drug
binding, residues 28–50 (red) undergo
significant conformational changes. The
dotted line depicts disordered residues
34–49. The metal-chelating residues Glu19,
His70, Glu19′ and His70′ are shown as cyan
balls and sticks, and binding-pocket residues
Glu134 and Glu134′ are depicted as blue
balls and sticks. The bound TPP molecules
are shown as purple balls and sticks, and the
metal ion is shown as a red sphere. (Figure
generated with Syby (Tripos)). (b) BmrR
fragment residues that contact TPP and the
water molecule Wat1 are shown in cyan; the
TPP molecule is shown in red. Dashed lines
indicate hydrogen bonds and contacts
between selected atoms with distances given
in Å. (Reproduced with permission from [11]).
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resistance pumps, such as ethidium bromide or benzalko-
nium chloride. They are amphipathic and have a positive
charge which is delocalized by the conjugated ring struc-
ture, an essential feature of a good permeant cation.
It is interesting to note in this regard that synthetic
hydrophobic cations were originally introduced into experi-
mental studies as probes to measure the membrane poten-
tial across cells and organelles [14]. This ingenious
approach made it possible to measure the membrane
potential (∆Ψ) of objects comparable in size to a microelec-
trode. By measuring the concentration of the cation after
accumulation into a cell or an organelle, the membrane
potential could be calculated from the Nernst equation. It
was argued that using synthetic molecules such as TPP
insulated this approach from possible interference by sub-
strate translocases, which one would not expect to
recognize these foreign substances. This logic worked well
in the case of mitochondria, and measurements of ∆Ψ in
these organelles went a long way in supporting Mitchell’s
chemiosmotic theory. The use of this method with bacte-
ria, as we can now see is problematic. B. subtilis, for
example, will detect TPP with BmrR and induce produc-
tion of the Bmr pump that will extrude TPP, messing up
the results of ∆Ψ measurements.
Berberine alkaloids appeared to be good substrates for the
NorA multidrug resistance pump [13] and for the QacA
multidrug resistance pump of S. aureus. Mutations knock-
ing out multidrug resistance pumps were found to turn
berberine, for example, into a very strong antibiotic. It
seems that this group of positively charged cations, which
are spread very widely in the plant world, are typical of the
cationic antimicrobial agents that the multidrug resistance
pumps evolved to counter. Berberine alkaloids do not,
however, bind to the Bmr pump (A.A. Neyfakh, personal
communication). Neither does ethidium bromide, which
is a good substrate of the BmrR.
Both ethidium and berberine are planar molecules,
whereas the good ligands for BmrR, such as rhodamine, are
not. Planar molecules would bind very well to a slit-shaped
pocket, but would not produce high-affinity interaction
with a cone-shaped binding site of BmrR. The Bmr pump,
like other multidrug resistance pumps, extrudes both
planar and aplanar hydrophobic cations perfectly well. This
probably suggests that the multidrug resistance pump has a
flexible hydrophobic binding pocket that will properly
envelope the incoming toxin. The QacR sensor binds both
the planar ethidium bromide and the aplanar rhodamine,
also suggestive of a more accommodating, ‘hand–glove’
type of flexible interaction with ligands. Not so with
BmrR, where the rigid binding pocket sets certain restric-
tions on shape and size, and will exclude poorly interacting
planar molecules. What are these cationic toxins that BmrR
steers towards its less discriminating pump?
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